Date: 2015-01-21
Type of information: Series C financing round
Company: RegenXBio (USA - MD)
Investors: Venrock (USA - CA) Brookside Capital (USA - MA) Deerfield Management (USA - NY) FoxKiser (USA - WA) Fidelity BioSciences (USA - MA) unnamed new investor
Amount: $30 million
Funding type: series C financing round
Planned used: RegenXBio plans to use the proceeds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, and expand its team. RegenXBio is leveraging its proprietary NAV® Technology to develop treatments for central nervous system (CNS) diseases such as Hurler Syndrome (MPS I) and Hunter Syndrome (MPS II), as well as other diseases in which gene therapy can make a meaningful difference in patients’ lives.
Others: * On January 21, 2015, RegenXBio, a leading biotechnology company in gene therapy, announced the completion of a $30 million Series C financing. Venrock and Brookside Capital led the financing with participation from Deerfield Management and an unnamed new investor. The company’s existing investors, FoxKiser and Fidelity BioSciences, also participated in the round. Camille Samuels, partner at Venrock, and Michael Gelman have joined REGENXBIO’s board of directors.
Therapeutic area: Rare diseases - Genetic diseases
